Blackhawk’s MindBio Therapeutics Announces Completion of World First Phase 1 Microdosing Clinical Trial
Successful completion of Phase 1 Clinical Trials
Blackhawk Growth Closes Investment in Blum Distributors
Vancouver, British Columbia – TheNewswire – April 28, 2022 – Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company”…
Blackhawk Growth Closes Investment in Stable Foods
Vancouver, British Columbia – TheNewswire – March 11, 2022 – Blackhawk Growth Corp. (CSE:BLR) (CSE:BLR) (OTC:BLRZF) (Frankfurt:0JJ) (the…
Blackhawk’s MindBio Therapeutics Announces Platinum Sponsorship of Plant Medicine Week in Malta
Co-Founder Justin Hanka to Deliver Keynote Address
Blackhawk Growth to Acquire Remaining 49% of NuWave Foods; NuWave Foods Changes Name to Stable Foods
Vancouver, British Columbia – TheNewswire – February 28, 2022– Blackhawk Growth Corp. (CSE:BLR) (CSE:BLR) (OTC:BLRZF) (Frankfurt: 0JJ) (the…
Blackhawk Subsidiary Digital Mind Technology Starts Phase 1 Development of Digital Therapeutic Platform and is on Track for Completion in Q2, 2022
Phase 1 development of new digital therapeutic platform underway
Blackhawk’s MindBio Therapeutics to Develop Psychedelic Medicine in Microdoses Ready for Commercial Use to Treat Major Depressive Disorder
Vancouver, British Columbia – TheNewswire – January 17, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CSE:BLR) (OTC:BLRZF) (Frankfurt:0JJ) (the…
Blackhawk’s MindBio Therapeutics to Develop Proprietary Drug Delivery Technology for Psychedelic Medicines
Vancouver, British Columbia – TheNewswire – January 04, 2022 – Blackhawk Growth Corp. (CSE:BLR) (CSE:BLR) (OTC:BLRZF) (Frankfurt:0JJ) (the…